Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (not Alteryx Therapeutics Ltd as indicated in metadata) covers the quarter ended March 31, 2018, and the nine-month period ending on that date. The registrant is an Australian biotechnology entity subject to ASX Listing Rule 4.7B.
Key Financial Metrics
Cash Flow (Nine Months Ended March 31, 2018):
- Operating Cash Flow: Net cash used in operating activities was $3,750,000 AUD.
- Investing Cash Flow: Net cash used in investing activities was $39,000 AUD.
- Financing Cash Flow: Net cash provided by financing activities was $44,000 AUD (receipt of funds upon expiry of term deposit).
- Net Change in Cash: Cash and cash equivalents increased by $21,884,000 AUD during the nine-month period.
- Cash Balance: Ending cash and cash equivalents were $17,625,000 AUD (comprising $9,508,000 in bank balances and $8,117,000 in call deposits).
Revenue and Profit:
- Revenue: The filing text does not provide a clear value for revenue or receipts from customers (listed as "-" in the cash flow statement).
- Profit/Loss: The filing text does not provide a clear value for net profit or loss; only cash flow data is presented.
- Government Grants: Received $3,023,000 AUD in government grants and tax incentives during the nine-month period.
Debt and Liquidity:
- Debt: No loan facilities or borrowings were drawn at quarter end.
- Liquidity: The company holds significant cash reserves relative to its estimated outflows.
Material Changes and Operational Costs
The primary cash outflows for the nine-month period were:
- Staff Costs: $2,607,000 AUD.
- Research and Development: $2,477,000 AUD.
- Administration and Corporate Costs: $1,768,000 AUD.
- Advertising and Marketing: $67,000 AUD.
There were no acquisitions or disposals of business entities reported during the period. The significant increase in cash balance ($21.9M) despite operating outflows suggests a substantial cash position at the beginning of the period or non-cash adjustments not detailed in this specific cash flow summary.
Guidance, Outlook, and Risks
Estimated Cash Outflows (Next Quarter):
- Total Estimated Outflows: $4,460,000 AUD.
- Breakdown: Research and development ($3,010,000), Staff costs ($900,000), Administration ($535,000), and Advertising ($15,000).
Management Commentary and Risks:
- The filing contains no specific management commentary, forward-looking guidance, or discussion of risks beyond the standard compliance statements.
- The company reports no outstanding loan facilities or credit standby arrangements.
Investor Verification Checklist
- Company Identity: Verify that the filing pertains to Prana Biotechnology Limited, not Alteryx Therapeutics Ltd.
- Revenue Source: Confirm the absence of customer receipts in the cash flow statement and investigate if revenue is recognized on an accrual basis not reflected here.
- Cash Position: Verify the source of the $21.9M increase in cash, as operating activities consumed $3.75M.
- Burn Rate: Compare the estimated next-quarter outflows ($4.46M) against the current cash balance ($17.6M) to assess runway.
- Government Grants: Review the nature and sustainability of the $3.0M in government grants received.